Characterization of long-term motor deficits in the 6-OHDA model of Parkinson's disease in the common marmoset

Behavioural Brain Research

Volumn 290, Issue , 2015, Pages 90-101

  Santana, M ^a,d,g   Palmer T ^b,c   Simplicio H ^a,e   Fuentes, R ^a,f   Petersson, P ^b  

^a Edmond and Lily Safra International Institute of Neuroscience Santos Dumont Institute   (Brazil)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^e DEPARTAMENTO DE FÍSICA   (Brazil)

^f UNIVERSITY OF CHILE   (Chile)

^g UNIVERSIDADE FEDERAL DO OESTE DO PARÁ   (Brazil)

Author keywords

Animal model; Motor behavior; Parkinson's disease

Indexed keywords

OXIDOPAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; BRAIN REGION; CALLITRICHINAE; CAUDATE NUCLEUS; CELL DENSITY; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; GAIT DISORDER; HEMISPHERE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOCOMOTION; MALE; MESENCEPHALON; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RATING SCALE; SYMPTOMATOLOGY; TREMOR; ANIMAL; CALLITHRIX; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; BEHAVIOR, ANIMAL; CALLITHRIX; DISEASE MODELS, ANIMAL; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; SEVERITY OF ILLNESS INDEX;

EID: 84929321647     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.04.037     Document Type: Article

References (22)

1. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
2. Eslamboli A. Marmoset monkey models of Parkinson's disease: Which model, when and why?. Brain Res Bull 2005, 68:140-149.
3. Przedborski S., Jackson-lewis V., Naini A.B., Petzinger G., Miller R., Akram M. The parkinsonian toxin (MPTP): a technical review of its utility and safety. J Neurochem 2001, 1265-1274.
4. Mitchell C.B.J., Hughes I.J., Carroll N. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav Pharmacol 1995, 6:492-507.
5. Annett L.E., Rogers D.C., Hernandez T.D., Dunnett S.B. Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain 1992, 115(3):825-856.
6. Ungerstedt U. 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol Ther B 1976, 2:37-40.
7. Klintenberg R., Arts J., Jongsma M., Wikström H., Gunne L., Andrén P.E. Motor effects of a dopamine stabilizer (GMC1111) in primate models of Parkinson and hemiparkinsonism. Eur J Pharmacol 2003, 459:231-237.
8. Eslamboli A., Romero-Ramos M., Burger C., Bjorklund T., Muzyczka N., Mandel R.J., et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007, 130:799-815.
9. Okano H., Hikishima K., Iriki A., Sasaki E. The common marmoset as a novel animal model system for biomedical and neuroscience research applications. Semin Fetal Neonatal Med 2012, 17:336-340.
10. Benabid A.L., Pollak P., Louveau A., Henry S., de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987, 50:344-346.
11. Benabid A.L., Pollak P., Hoffmann D., Gervason C., Hommel M., Perret J.E., et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991, 337:403-406.
12. Fuentes R., Petersson P., Nicolelis M.A.L. Restoration of locomotive function in Parkinson's disease by spinal cord stimulation: mechanistic approach. Eur J Neurosci 2010, 32:1100-1108.
13. Fuentes R., Petersson P., Siesser W.B., Caron M.G., Nicolelis M.A.L. Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. Science 2009, 323:1578-1582.
14. H. (Heinz) Stephan, G. (Georg) Baron, W.K. (WalterK. Schwerdtfeger, The brain of the common marmoset (Callithrix jacchus): a stereotaxic atlas/H. Stephan, G., Baron, W.K. Schwerdtfeger, (1980).
15. Verhave P.S.R.a., Vanwersch P., van Helden H.P.M., Smit A.B., Philippens I.H.C.H.M. Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease. Behav Brain Res 2009, 200:214-219.
16. Bankiewicz K.S., Sanchez-Pernaute R., Oiwa Y., Kohutnicka M., Cummins A., Eberling J. Preclinical Models of Parkinson's Disease. in: Curr. Protoc. Neurosci. 2001, John Wiley & Sons, Inc.
17. Hansard M.J., Smith L.A., Jackson M.J., Cheetham S.C., Jenner P. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther 2002, 303:952-958.
18. Fahn S., Elton R.L.U.D. Committee, others Unified Parkinson's disease rating scale. Recent Dev Park Dis 1987, 2:153-163.
19. Eslamboli A., Baker H.F., Ridley R.M., Annett L.E. Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys. Exp Neurol 2003, 183:418-429.
20. Freire M.A.M., Morya E., Faber J., Santos J.R., Guimaraes J.S., Lemos N.A.M., et al. Comprehensive Analysis of Tissue Preservation and Recording Quality from Chronic Multielectrode Implants. PLoS One 2011, 6:e27554.
21. Paxinos G., Watson C., Petrides M., Rosa M., Tokuno H. The Marmoset Brain in Stereotaxic Coordinates 2012, Academic Press, San Diego.
22. Mitchell I.J., Carroll C.B. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neurosci Biobehav Rev 1997, 21:469-475.